Phadia

Movers & Shakers

Premium

Olink Bioscience this week appointed Simon Fredriksson as its new president and CEO, replacing Bjorn Ekstrom, who has led the company since its founding in 2004 and will be joining its board of directors.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today raised its adjusted EPS and revenues guidance for full-year 2011 following the completion of its purchase of specialty diagnostics firm Phadia.

The company has entered a bridge credit agreement for $2 billion and a revolving credit agreement for up to $1 billion.

The acquisition, expected to close in the fourth quarter, will give Thermo Fisher Phadia's immunoassay-based allergy testing and autoimmune disease-testing products.

The acquisition will significantly expand Thermo Fisher's specialty diagnostics business from current annual revenues of around $1.4 billion to roughly $1.9 billion.

The company's Multiplexing Diagnostics division will use the arrayer to develop molecular tools, including protein biomarkers, to diagnose allergy and autoimmunity.

Phadia will use the 2470 in its research efforts to characterize new allergens and to discover biomarker signatures that can be used in the molecular diagnosis of allergies and autoimmune diseases.

The Associated Press reports that the US government wasted $341,000 on travel by former Health and Human Services Secretary Tom Price.

Women who post YouTube science videos get more critical comments and more comments about their appearance than male video hosts, the New York Times reports.

The Wall Street Journal writes that participating in genetic research brings up the specter of past research ethics lapses for some African Americans.

In PLOS this week: sequences influencing yeast prion aggregation or degradation, dengue virus genetic variants affect transmission dynamics, and more.